HRHeather Joan Ross

Heather Joan Ross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Heather Joan Ross has a total of 561 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incidence of Dementia and Subsequent Outcomes in Patients With Heart Failure

    by Paul Tieu, Raed A. Joundi, Finlay A. McAlister, Moira K. Kapral, Nadia Khan, Richard H. Swartz, Clare L. Atzema, Peter C. Austin, Philip A. Barber, Filio Billia, et al.

  • Open Access

    Acute cellular rejection after heart transplantation: validation of HEARTBiT, a transcriptomic biomarker

    by Casey P Shannon, Sara Assadian, Ashwini Rajasekaran, Chengliang Yang, Estefanía Espín, Le Lam, Robert Balshaw, Michael A Seidman, Chi K Lai, Heather J Ross, et al.

    Background and Aims: Acute cellular rejection (ACR) risk is highest within 60 days of heart transplantation (HTx), yet existing minimally invasive surveillance tools lack validation for this high-risk period. This study prospectively validated the diagnostic accuracy of HEARTBiT, a transcriptomic biomarker for detecting moderate-to-severe ACR, including during the early post-operative period. Methods: This prospective diagnostic accuracy study (NCT03575910) enrolled consecutive adult HTx recipients at four tertiary clinical centres. The diagnostic performance of HEARTBiT was evaluated in 336 visits from 117 participants against centralized expert consensus panel endomyocardial biopsy grades. An exploratory analysis of 246 serial visits from 31 participants evaluated the prognostic potential of tracking individual transcriptomic trajectories over time. Results: HEARTBiT accurately detected moderate-to-severe ACR (ISHLT ≥2R) with an overall area under the curve (AUC) of 0.78 [95% confidence interval (CI) 0.70–0.86]. Performance was stable early post-HTx (≤60 days: AUC = 0.78, 95% CI 0.65–0.90) and beyond 60 days (AUC = 0.80, 95% CI 0.72–0.87). Prioritizing high sensitivity (89% early, 100% late; corresponding to ≤1 missed ACR overall) yielded a specificity of 56% in the early period (≤60 days) and 49% beyond 60 days using the pre-specified cutoff (>0.54). Alternatively, adopting an exploratory time-varying threshold (>0.68) beyond 60 days yielded 83% sensitivity and 76% specificity. Importantly, HEARTBiT scores increased weeks before histological detection of ACR by tissue biopsy (slope-based AUC = 0.78, 95% CI 0.60–0.96). Conclusions: HEARTBiT provides a reliable, minimally invasive rule-out signal for moderate-to-severe ACR across the first year post-HTx, particularly during the high-risk early post-operative period. Serial tracking of HEARTBiT score trajectories has potential for prognosis of progression to ACR. These findings support the clinical utility of this biomarker in safely sparing more than 50% of protocol surveillance endomyocardial biopsies.


  • Sex-Specific Associations between Long-term Air Pollution Exposure and Coronary Atherosclerosis at Cardiac CT

    by Felipe Castillo, Aly Muhammad Ladak, Chloe DesRoche, Scott Delaney, Rachel C. Nethery, Paaladinesh Thavendiranathan, Heather Ross, Kate Hanneman

    Long-term exposure to air pollution, even at moderate levels, is independently associated with greater coronary artery calcium extent and total plaque burden at cardiac CT.

  • Open Access

    Remote monitoring of heart failure exacerbations using a smartwatch

    by Yuan Gao, Yasbanoo Moayedi, Farid Foroutan, Bhavish Verma, Ben Kim, Enza De Luca, Margaret Brum, Darshan H. Brahmbhatt, Joe Duhamel, Anne Simard, et al.

    Heart failure (HF) involves cycles of remission and exacerbation, which are poorly characterized by static disease measures. Consumer wearables have an understudied potential for daily monitoring of HF symptoms. Here we report results from an observational cohort of free-living patients over a median of 94.5 d with HF in the Ted Rogers Understanding Exacerbations of HF (TRUE-HF) study. The study measured the ability of Apple Watch data to predict peak oxygen uptake (pVO2) as measured using in-clinic cardiopulmonary exercise testing (CPET). A deep learning model was trained with data from 154 patients (46 women, 108 men) and validated on a held-out set of 63 patients (24 women, 39 men) for determining wearable-derived daily pVO2, which correlated strongly with CPET-measured pVO2 (Pearson’s correlation = 0.85). Each 10% drop in wearable-derived daily pVO2 was associated with a 3.62-fold increased hazard ratio (HR) for unplanned healthcare events (95% confidence interval (CI), 1.37–9.55; P < 0.01), which occurred at a median of 7.4 d after the first 10% drop in wearable-derived pVO2. These findings were externally validated in an independent external cohort from the All of Us Research Program using a crossplatform model that accounted for the reduced-sensor capacities available in this external cohort. Using this reduced-sensor variant of the model, drops in wearable-derived daily pVO2 were associated with unplanned healthcare utilization (HR 1.32, 95% CI 1.03–1.69; P = 0.03), which occurred at a median of 21 d after the first 10% drop in wearable-derived pVO2. These results indicate that wearable-derived daily pVO2 provides earlier and improved risk discrimination compared with existing wearable fitness estimates and established clinical markers and offers a scalable and generalizable approach for longitudinal HF research and monitoring.


  • Open Access

    Lessons learned from piloting a heart failure-based remote management care system in a general internal medicine program: A qualitative evaluation

    by Sarah Vc Lawrason, Heather J Ross, Anne Simard, Tarek Abdelhalim, William K Silverstein

    Objective: Medly is a remote patient management (RPM) tool that allows patients with heart failure (HF) to record daily measures to inform health status and receive personalized care instructions by a validated algorithm. Medly has been standard-of-care for patients with HF in the Cardiology Division at University Health Network since 2016. While patients with HF are often admitted to general internal medicine (GIM), there are few HF RPM programs used in the GIM setting. We piloted Medly for patients discharged from GIM in the summer of 2023. The purpose of this study was to understand staff factors that enabled or inhibited spread and scale of Medly into a GIM setting. Methods: Semistructured interviews were conducted with 13 staff involved in the planning, delivery, and implementation of Medly in the GIM setting. Interviews were recorded and transcribed verbatim. Data were analyzed using deductive thematic analysis informed by the Consolidated Framework for Implementation Research. Results: Implementation factors included: (1) communicative staff, (2) Medly adaptability and relative advantage, (3) need for long-term funding, (4) leadership engagement and learning-centered culture, and (5) sociodemographic characteristics of patients. Conclusion: This study offers valuable insight into how an RPM can be adopted from the Cardiology to GIM context. Key enablers include providing appropriate staff time and compensation, engaging leadership early and often, modifying the application for the setting, and considering equity with respect to language barriers. A larger pilot with more than 10 patients actively embedded in the GIM pathway is required for further scale of the program.

  • Open Access

    A Quality Improvement Initiative on Documentation of Guideline-Directed Medical Therapy Implementation Among Primary Prevention CRT-D Implant

    by Sadia Wasik, Yasbanoo Moayedi, Andrew C.T. Ha, Krishnakumar Nair, Ana Carolina Alba, Katherine V. Westcott, Stephen Chan, Barry Rubin, Heather Ross

  • Open Access

    Association Between the Emergency Heart Failure Mortality Risk Grade (EHMRG30-ST) and Costs of Care

    by Karem Abdul-Samad, Shijie Zhou, Maria Santiago-Jimenez, Jiming Fang, Steven Chu, Clare L. Atzema, Ava John-Baptiste, Peter C. Austin, Joshua G. Lee, Lusine Abrahamyan, et al.

  • Open Access

    Use of Indigenous-Based Methodologies to Enhance the Understanding of Local Context in Ugandan Communities: Protocol for a Mixed Methods Study

    by Sahr Wali, Jeremy I Schwartz, Justice Seidel, Jenipher Kamarembo, Jenifer Atala, Ann R Akiteng, Martha Nabadda, Cinderella N Muhangi, Angela Mashford-Pringle, Heather Ross, et al.

    Background: With many socially disadvantaged populations experiencing a higher level of illness than the general population, health research has begun to recognize the impact of social determinants on health outcomes. Community-based research has increasingly been used to understand the complexities of the local context. However, given the number of interdependent factors influencing individual well-being, no single methodology can explore this level of complexity alone. To put context into perspective, research processes need to shift from the sole use of Western methodologies and, instead, incorporate collaborative methods from nontraditional research. Specifically, Indigenous methodologies have been developed to better understand the complexity of context within multiple worldviews, but current studies have failed to apply these approaches within other cultural settings. Objective: This mixed methods study will use Western and Indigenous methodologies to adapt a digital health program for remote communities in Uganda. Methods: Using the principles of community-based research and user-centered design, a 4-phase mixed methods study will be conducted. The Indigenous method of 2-eyed seeing will be used to promote a reflexive engagement strategy throughout all study phases. Phase 1 will focus on partnership building to codevelop the project priorities and study design. Phase 2 will involve a needs assessment to elicit a context-focused understanding of the local clinic and community environment. Phase 3 will involve a series of system adaptations to co-design the program. Phase 4 will consist of a community-based field study to evaluate the usability and cultural relevance of the adapted program. Results: This study was approved by the Makerere University School of Medicine Research and Ethics Committee (Mak-SOMREC-2021-63) and the University Health Network Research Ethics Board (20-6022). This protocol provides a novel strategy leveraging a range of community-based methods to ensure that the contextual significance of each community’s challenges is reflected in the design of the Medly Uganda program. Partnership building was initiated in June 2019, and the first stage of data collection in phase 2 began in January 2021. At the time of manuscript submission, phases 1 to 3 have been completed. Phase 4 data analysis is ongoing and expected to be completed in October 2025. Conclusions: Integrating the community’s local knowledge into the design of the Medly Uganda program will lead to the development of meaningful interventions that improve health outcomes. International Registered Report Identifier (IRRID): DERR1-10.2196/75136

  • Developments in Digital Wearable in Heart Failure and the Rationale for the Design of TRUE-HF (Ted Rogers Understanding of Exacerbations in Heart Failure) Apple CPET Study

    by Yasbanoo Moayedi, Farid Foroutan, Yuan Gao, Ben Kim, Enza De Luca, Margaret Brum, Darshan H. Brahmbhatt, Joe Duhamel, Anne Simard, Christopher McIntosh, et al.

    BACKGROUND: Heart failure (HF) is a highly prevalent condition characterized by exercise intolerance, an important metric for ambulatory prognostication. However, current methods to assess exercise capacity are often limited to tertiary HF centers, lacking scalability or accessibility. Wearable devices can enable near-continuous dynamic biometrics including exercise tolerance. METHODS: Leveraging the capabilities of Apple Watch and a custom application, the TRUE-HF (Ted Rogers Understanding of Exacerbations in Heart Failure) Apple cardiopulmonary exercise testing study aims to investigate whether HealthKit data from Apple Watch can estimate cardiorespiratory fitness, as compared with the gold standard peak oxygen uptake from cardiopulmonary exercise testing. The TRUE-HF study will evaluate the potential impact of wearable technology in the functional assessment of ambulatory patients with HF. The primary end point is to use HealthKit variables to estimate a TRUE-HF peak oxygen uptake. We outline key features of this trial designed to reduce the burden of wearable technology. In addition, we highlight the benefits of various machine learning analyses, with a particular focus on transformer models for the wearable space. CONCLUSIONS: Using cutting-edge wearable technology and machine learning analytics, TRUE-HF may provide state-of-the-art assessment of functional capacity by measuring participant-generated free-world data. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05008692.